153 related articles for article (PubMed ID: 12549992)
1. [The current state of hormonal prevention of coronary heart disease in menopausal women].
Wenger NK
Rev Esp Cardiol; 2003 Jan; 56(1):1-8. PubMed ID: 12549992
[TBL] [Abstract][Full Text] [Related]
2. [Menopausal hormone therapy and cardiovascular disease].
Wenger NK
Rev Esp Cardiol; 2006 Oct; 59(10):1058-69. PubMed ID: 17125716
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy trials: an update.
Duvernoy CS; Mosca L
Curr Atheroscler Rep; 2002 Mar; 4(2):156-60. PubMed ID: 11822980
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
5. Design and methods of the Raloxifene Use for The Heart (RUTH) study.
Mosca L; Barrett-Connor E; Wenger NK; Collins P; Grady D; Kornitzer M; Moscarelli E; Paul S; Wright TJ; Helterbrand JD; Anderson PW
Am J Cardiol; 2001 Aug; 88(4):392-5. PubMed ID: 11545760
[TBL] [Abstract][Full Text] [Related]
6. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
Mobasseri S; Liebson PR; Klein LW
Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone therapy and cardiovascular protection: state of the data 2003.
Wenger NK
J Am Med Womens Assoc (1972); 2003; 58(4):236-9. PubMed ID: 14640254
[TBL] [Abstract][Full Text] [Related]
8. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
9. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial.
Mosca L
Ann N Y Acad Sci; 2001 Dec; 949():181-5. PubMed ID: 11795352
[TBL] [Abstract][Full Text] [Related]
10. Novel agents to modulate oestrogen action.
Dardes RC; Jordan VC
Br Med Bull; 2000; 56(3):773-86. PubMed ID: 11255561
[TBL] [Abstract][Full Text] [Related]
11. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Vogelvang TE; van der Mooren MJ; Mijatovic V; Kenemans P
Drugs; 2006; 66(2):191-221. PubMed ID: 16451093
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial.
Wenger NK; Barrett-Connor E; Collins P; Grady D; Kornitzer M; Mosca L; Sashegyi A; Baygani SK; Anderson PW; Moscarelli E
Am J Cardiol; 2002 Dec; 90(11):1204-10. PubMed ID: 12450599
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
Duvernoy CS; Yeo AA; Wong M; Cox DA; Kim HM
J Womens Health (Larchmt); 2010 Aug; 19(8):1459-65. PubMed ID: 20626269
[TBL] [Abstract][Full Text] [Related]
15. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.
Collins P; Mosca L; Geiger MJ; Grady D; Kornitzer M; Amewou-Atisso MG; Effron MB; Dowsett SA; Barrett-Connor E; Wenger NK
Circulation; 2009 Feb; 119(7):922-30. PubMed ID: 19204301
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
Saitta A; Altavilla D; Cucinotta D; Morabito N; Frisina N; Corrado F; D'Anna R; Lasco A; Squadrito G; Gaudio A; Cancellieri F; Arcoraci V; Squadrito F
Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1512-9. PubMed ID: 11557681
[TBL] [Abstract][Full Text] [Related]
17. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
18. Postmenopausal hormone use for cardioprotection: what we know and what we must learn.
Wenger NK
Curr Opin Cardiol; 1999 Jul; 14(4):292-7. PubMed ID: 10448608
[TBL] [Abstract][Full Text] [Related]
19. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
Draper MW
Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
[TBL] [Abstract][Full Text] [Related]
20. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
Ensrud KE; Stock JL; Barrett-Connor E; Grady D; Mosca L; Khaw KT; Zhao Q; Agnusdei D; Cauley JA
J Bone Miner Res; 2008 Jan; 23(1):112-20. PubMed ID: 17892376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
